GlaxoSmithKline S.A.E Statistics

Total Valuation

GlaxoSmithKline S.A.E has a market cap or net worth of EGP 3.28 billion. The enterprise value is 3.70 billion.

Market Cap	3.28B
Enterprise Value	3.70B

Important Dates

The next estimated earnings date is Monday, March 3, 2025.

Earnings Date	Mar 3, 2025
Ex-Dividend Date	Jul 18, 2024

Share Statistics

GlaxoSmithKline S.A.E has 83.51 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	83.51M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.43M

Valuation Ratios

The trailing PE ratio is 27.40.

PE Ratio	27.40
Forward PE	n/a
PS Ratio	1.17
PB Ratio	1.70
P/TBV Ratio	1.70
P/FCF Ratio	92.46
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.07, with an EV/FCF ratio of 104.40.

EV / Earnings	30.94
EV / Sales	1.32
EV / EBITDA	6.07
EV / EBIT	6.62
EV / FCF	104.40

Financial Position

The company has a current ratio of 1.75, with a Debt / Equity ratio of 0.33.

Current Ratio	1.75
Quick Ratio	0.48
Debt / Equity	0.33
Debt / EBITDA	1.00
Debt / FCF	17.91
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 6.16% and return on invested capital (ROIC) is 15.79%.

Return on Equity (ROE)	6.16%
Return on Assets (ROA)	10.02%
Return on Capital (ROIC)	15.79%
Revenue Per Employee	3.51M
Profits Per Employee	149,442
Employee Count	800
Asset Turnover	0.77
Inventory Turnover	1.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +5.59% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+5.59%
50-Day Moving Average	40.96
200-Day Moving Average	33.74
Relative Strength Index (RSI)	42.72
Average Volume (20 Days)	44,050

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GlaxoSmithKline S.A.E had revenue of EGP 2.81 billion and earned 119.55 million in profits. Earnings per share was 1.43.

Revenue	2.81B
Gross Profit	1.17B
Operating Income	582.85M
Pretax Income	283.25M
Net Income	119.55M
EBITDA	620.97M
EBIT	582.85M
Earnings Per Share (EPS)	1.43

Full Income Statement

Balance Sheet

The company has 212.21 million in cash and 634.65 million in debt, giving a net cash position of -422.44 million or -5.06 per share.

Cash & Cash Equivalents	212.21M
Total Debt	634.65M
Net Cash	-422.44M
Net Cash Per Share	-5.06
Equity (Book Value)	1.93B
Book Value Per Share	23.07
Working Capital	1.28B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 120.87 million and capital expenditures -85.45 million, giving a free cash flow of 35.43 million.

Operating Cash Flow	120.87M
Capital Expenditures	-85.45M
Free Cash Flow	35.43M
FCF Per Share	0.42

Full Cash Flow Statement

Margins

Gross margin is 41.79%, with operating and profit margins of 20.77% and 4.26%.

Gross Margin	41.79%
Operating Margin	20.77%
Pretax Margin	10.09%
Profit Margin	4.26%
EBITDA Margin	22.12%
EBIT Margin	20.77%
FCF Margin	1.26%

Dividends & Yields

This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.91%.

Dividend Per Share	0.75
Dividend Yield	1.91%
Dividend Growth (YoY)	-80.00%
Years of Dividend Growth	2
Payout Ratio	61.44%
Buyback Yield	n/a
Shareholder Yield	1.91%
Earnings Yield	3.65%
FCF Yield	1.08%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GlaxoSmithKline S.A.E has an Altman Z-Score of 3.02.

Altman Z-Score	3.02
Piotroski F-Score	n/a